IL134842A0 - Method of delivering genes to antigen presenting cells of the skin - Google Patents
Method of delivering genes to antigen presenting cells of the skinInfo
- Publication number
- IL134842A0 IL134842A0 IL13484298A IL13484298A IL134842A0 IL 134842 A0 IL134842 A0 IL 134842A0 IL 13484298 A IL13484298 A IL 13484298A IL 13484298 A IL13484298 A IL 13484298A IL 134842 A0 IL134842 A0 IL 134842A0
- Authority
- IL
- Israel
- Prior art keywords
- skin
- presenting cells
- antigen presenting
- delivering genes
- genes
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5893397P | 1997-09-15 | 1997-09-15 | |
PCT/US1998/019498 WO1999013915A1 (en) | 1997-09-15 | 1998-09-15 | Method of delivering genes to antigen presenting cells of the skin |
Publications (1)
Publication Number | Publication Date |
---|---|
IL134842A0 true IL134842A0 (en) | 2001-05-20 |
Family
ID=22019811
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13484298A IL134842A0 (en) | 1997-09-15 | 1998-09-15 | Method of delivering genes to antigen presenting cells of the skin |
IL134842A IL134842A (en) | 1997-09-15 | 2000-03-01 | A gene transfer system for vaccination through the skin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL134842A IL134842A (en) | 1997-09-15 | 2000-03-01 | A gene transfer system for vaccination through the skin |
Country Status (18)
Country | Link |
---|---|
US (2) | US6420176B1 (de) |
EP (1) | EP1024836B1 (de) |
JP (1) | JP2001516729A (de) |
KR (1) | KR100615117B1 (de) |
CN (1) | CN100391542C (de) |
AP (1) | AP1427A (de) |
AT (1) | ATE347911T1 (de) |
AU (1) | AU754425B2 (de) |
BR (1) | BR9813202B1 (de) |
CA (1) | CA2302316A1 (de) |
DE (1) | DE69836643T2 (de) |
EA (1) | EA003832B1 (de) |
ES (1) | ES2279580T3 (de) |
IL (2) | IL134842A0 (de) |
NO (1) | NO327491B1 (de) |
NZ (1) | NZ503334A (de) |
OA (1) | OA11612A (de) |
WO (1) | WO1999013915A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
AU754425B2 (en) * | 1997-09-15 | 2002-11-14 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
AU2669599A (en) * | 1998-02-12 | 1999-08-30 | Regents Of The University Of California, The | Compositions for receptor/liposome mediated transfection and methods of using same |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
US20020006412A1 (en) * | 2000-04-28 | 2002-01-17 | Roberts Bruce L. | Preparation and use of particulates composed of adenovirus particles |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
US8357377B2 (en) * | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
WO2004065575A2 (en) | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
JP4332558B2 (ja) * | 2003-12-09 | 2009-09-16 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニ細胞を介した非食作用性哺乳動物細胞への標的化遺伝子送達 |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
CA2549605C (en) | 2003-12-23 | 2013-05-07 | Cythera, Inc. | Definitive endoderm |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
US8586357B2 (en) | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
EP2377922B1 (de) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1-exprimierendes Endoderm |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US8007814B2 (en) | 2004-06-16 | 2011-08-30 | University Of Massachusetts | Therapy for lysosomal enzyme deficiencies |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
EP1786896B1 (de) | 2004-07-09 | 2018-01-10 | Viacyte, Inc. | Verfahren zur identifizierung von faktoren zur differenzierung von definitiver entodermis |
US8187878B2 (en) | 2004-08-13 | 2012-05-29 | University Of Georgia Research Foundation, Inc. | Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors |
KR20060073172A (ko) * | 2004-12-24 | 2006-06-28 | 재단법인서울대학교산학협력재단 | 생체 고분자/유전자 복합체 |
BRPI0501037B8 (pt) * | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | uso de crotamina e composição |
JP5489462B2 (ja) * | 2005-10-24 | 2014-05-14 | ユニバーシティ オブ マサチューセッツ | 骨病状の遺伝子治療のための組成物およびそれらの使用法 |
CN101351547A (zh) | 2005-10-27 | 2009-01-21 | 赛瑟拉公司 | 表达pdx1的背侧和腹侧前肠内胚层 |
EP4112718A1 (de) | 2006-03-02 | 2023-01-04 | ViaCyte, Inc. | Endokrine vorläuferzellen, pankreashormon-exprimierende zellen und herstellungsverfahren |
US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
US7989204B2 (en) | 2006-04-28 | 2011-08-02 | Viacyte, Inc. | Hepatocyte lineage cells |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
CA2704056A1 (en) * | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
EP2217625B1 (de) | 2007-11-08 | 2021-08-04 | Precision Biologics, Inc. | Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
ES2667493T3 (es) | 2008-11-14 | 2018-05-11 | Viacyte, Inc. | Encapsulación de células pancreáticas derivadas de células madre humanas pluripotentes |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
HU0900117D0 (en) | 2009-02-26 | 2009-04-28 | Genetic Immunity Kutatasi | Topical or transdermal delivery kit |
WO2010125544A1 (en) * | 2009-04-30 | 2010-11-04 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
CN104208716A (zh) * | 2009-11-23 | 2014-12-17 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
CN103108642B (zh) | 2010-03-24 | 2015-09-23 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
EP2550000A4 (de) | 2010-03-24 | 2014-03-26 | Advirna Inc | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
US9205099B2 (en) | 2010-06-22 | 2015-12-08 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
CN102146416B (zh) * | 2010-12-30 | 2013-03-13 | 江苏大学 | 阳离子化杏鲍菇多糖纳米粒基因传递系统及其制法 |
EP2527440A1 (de) * | 2011-05-27 | 2012-11-28 | Institut Curie | Krebsbehandlung durch Kombination von Doppelstrangbruch nachahmenden DNA-Molekülen mit Hyperthermie |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
WO2015024022A2 (en) | 2013-08-16 | 2015-02-19 | University Of Rochester | Designed peptides for tight junction barrier modulation |
KR102689262B1 (ko) | 2014-09-05 | 2024-07-30 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
LT3325623T (lt) | 2015-07-23 | 2019-10-25 | Inst Curie | Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti |
CN105396140B (zh) * | 2015-12-02 | 2019-07-02 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
EP3980054A1 (de) | 2019-06-05 | 2022-04-13 | University Of Rochester | Neue konstruierte inhibitoren der bildung von dichten verbindungen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
AU2242799A (en) * | 1994-02-22 | 1999-05-27 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
CA2194488A1 (en) * | 1994-08-05 | 1996-02-15 | Tod Paul Holler | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
CA2223921A1 (en) * | 1995-06-07 | 1996-12-19 | Francis C. Szoka, Jr. | Stabilization of polynucleotide complexes |
DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
AU726623B2 (en) * | 1996-02-21 | 2000-11-16 | Julianna Lisziewicz | Methods and compositions for protective and therapeutic genetic immunization |
FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
AU754425B2 (en) * | 1997-09-15 | 2002-11-14 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
-
1998
- 1998-09-15 AU AU93980/98A patent/AU754425B2/en not_active Ceased
- 1998-09-15 ES ES98947128T patent/ES2279580T3/es not_active Expired - Lifetime
- 1998-09-15 CN CNB988111675A patent/CN100391542C/zh not_active Expired - Fee Related
- 1998-09-15 US US09/153,198 patent/US6420176B1/en not_active Expired - Fee Related
- 1998-09-15 EA EA200000325A patent/EA003832B1/ru not_active IP Right Cessation
- 1998-09-15 AT AT98947128T patent/ATE347911T1/de not_active IP Right Cessation
- 1998-09-15 IL IL13484298A patent/IL134842A0/xx active IP Right Grant
- 1998-09-15 DE DE69836643T patent/DE69836643T2/de not_active Expired - Lifetime
- 1998-09-15 JP JP2000511529A patent/JP2001516729A/ja active Pending
- 1998-09-15 CA CA002302316A patent/CA2302316A1/en not_active Abandoned
- 1998-09-15 EP EP98947128A patent/EP1024836B1/de not_active Expired - Lifetime
- 1998-09-15 KR KR1020007002661A patent/KR100615117B1/ko not_active IP Right Cessation
- 1998-09-15 BR BRPI9813202-4A patent/BR9813202B1/pt not_active IP Right Cessation
- 1998-09-15 AP APAP/P/2000/001762A patent/AP1427A/en active
- 1998-09-15 NZ NZ503334A patent/NZ503334A/en unknown
- 1998-09-15 WO PCT/US1998/019498 patent/WO1999013915A1/en active IP Right Grant
- 1998-09-15 OA OA1200000074A patent/OA11612A/en unknown
-
2000
- 2000-03-01 IL IL134842A patent/IL134842A/en not_active IP Right Cessation
- 2000-03-09 NO NO20001244A patent/NO327491B1/no not_active IP Right Cessation
-
2002
- 2002-02-21 US US10/081,922 patent/US7910562B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1024836B1 (de) | 2006-12-13 |
WO1999013915A1 (en) | 1999-03-25 |
BR9813202B1 (pt) | 2011-11-01 |
NZ503334A (en) | 2002-05-31 |
KR20010030598A (ko) | 2001-04-16 |
AP1427A (en) | 2005-06-07 |
AU754425B2 (en) | 2002-11-14 |
EP1024836A4 (de) | 2003-07-02 |
OA11612A (en) | 2004-08-13 |
AU9398098A (en) | 1999-04-05 |
CN1278739A (zh) | 2001-01-03 |
KR100615117B1 (ko) | 2006-08-22 |
DE69836643D1 (de) | 2007-01-25 |
IL134842A (en) | 2009-02-11 |
BR9813202A (pt) | 2000-08-29 |
US6420176B1 (en) | 2002-07-16 |
CN100391542C (zh) | 2008-06-04 |
DE69836643T2 (de) | 2007-09-27 |
ATE347911T1 (de) | 2007-01-15 |
NO327491B1 (no) | 2009-07-20 |
NO20001244D0 (no) | 2000-03-09 |
EP1024836A1 (de) | 2000-08-09 |
CA2302316A1 (en) | 1999-03-25 |
US20020193333A1 (en) | 2002-12-19 |
JP2001516729A (ja) | 2001-10-02 |
AP2000001762A0 (en) | 2000-03-31 |
US7910562B2 (en) | 2011-03-22 |
EA003832B1 (ru) | 2003-10-30 |
ES2279580T3 (es) | 2007-08-16 |
NO20001244L (no) | 2000-05-15 |
EA200000325A1 (ru) | 2000-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2000001762A0 (en) | Method of delivering genes to antigen presenting cells of the skin | |
IL136113A0 (en) | Modified antibodies with enhanced ability to elicit an anti-idiotype response | |
IL131486A0 (en) | Gene sequencer and methods | |
AU6687696A (en) | Transgenic swine and swine cells having human hla genes | |
EP1119365A4 (de) | Zusammensetzung und methode zur verwendung von tumorzellen | |
HUP9800329A3 (en) | Nucleic acid constructs for the cell cycle regulated expression of structural genes | |
EP0927270A4 (de) | Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna | |
AU7704498A (en) | Human frp and fragments thereof including methods for using them | |
HK1028961A1 (en) | Compositions and methods for enhancing delivery of therapeutic agents to cells | |
GB9515356D0 (en) | Improvements in or relating to delivery of nucleic acid | |
EP1109582A4 (de) | Verfahren zur verstärkung und beschränkung der genexpression | |
AU2087799A (en) | Diagnostic and therapeutic methods based upon valpha24jalphaq t cells | |
ZA958381B (en) | Regulated genes by stimulation of chondrocytes with 1l-1beta | |
EP0804550A4 (de) | Die ex vivo aktivierung von immunzellen | |
GB9519776D0 (en) | Materials and methods relating to the transfer of nucleic acid into stem cells | |
GB9721075D0 (en) | Materials and methods relating to the stimulation of cells | |
HK1023147A1 (en) | Methods for identifying genes essential to the growth of an organism | |
AU9221098A (en) | Selective expression of genes in plants | |
IL117594A0 (en) | Gene expression in mammalian cells | |
AU4459100A (en) | Cell cycle genes and methods of use | |
EP1003849A4 (de) | Verfahren zur verminderung der expressionsvarianz von transgenen in pflanzenzellen | |
PL335483A1 (en) | Method of obtaining vaccines against superficial cell proteins | |
GB9720216D0 (en) | Delivery of therapeutic genes to haematopoietic stem cells | |
IL159948A0 (en) | Stimulation of hematopoietic cells in vitro | |
GB9705007D0 (en) | Improvements in or relating to therapeutic genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |